SAN DIEGO , Dec. 9, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to
SAN DIEGO , Oct. 14, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the pricing of an underwritten public
Discussion to Feature Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression in Lung Cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer,
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the voluntary resignation of Bill Kachioff, Senior Vice President and Chief Financial Officer,
More than 99 million healthcare consumers now have access to Biocept's suite of blood-based diagnostics through healthcare payors and plans SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
Conducted by leading breast oncologists from UCSF under a grant from the California Breast Cancer Research Program and the University of California , San Francisco Brain Spore, the study will analyze results from cerebrospinal fluid using Biocept’s CNSide™ assay with results from blood samples SAN
SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that President and Chief Executive Officer Michael Nall will participate in a panel
SAN DIEGO --(BUSINESS WIRE)--May 17, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023 , its common stock will
SAN DIEGO , Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that, as a result of the Company's one-for-ten reverse stock
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable
